|
Synonyms: Compound 424 [US11254674] | compound of formula (II) [WO2020190780] | FT-7051 | FT7051
Compound class:
Synthetic organic
Comment: Pocenbrodib (FT-7051) is an inhibitor that targets the bromodomains of the p300 (E1A-associated protein p300) and CBP (CREB binding protein) histone acetyltransferase enzymes [1,3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Luke G. (2020)
Inhibiting cyclic amp-responsive element-binding protein (creb). Patent number: WO2020190780A1. Assignee: Forma Therapeutics Inc. Priority date: 13/03/2020. Publication date: 24/09/2020. |
|
2. Schiller SER, Herbertz T, Li H, Graves B, Mischke S, West A, Downing JR, Ericsson A. (2022)
Inhibiting CREB binding protein (CBP). Patent number: US11254674B2. Assignee: Forma Therapeutics Inc. Priority date: 08/06/2020. Publication date: 22/02/2022. |
|
3. Wu X, Zhang X, Tang S, Wang Y. (2025)
The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors. Cell Biol Toxicol, 41 (1): 32. [PMID:39825161] |